<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3709">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058627</url>
  </required_header>
  <id_info>
    <org_study_id>H-16039929</org_study_id>
    <nct_id>NCT03058627</nct_id>
  </id_info>
  <brief_title>Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>NOTION-3</acronym>
  <official_title>Routine Revascularization With Percutaneous Coronary Intervention in Patients With Coronary Artery Disease Undergoing Transcatheter Aortic Valve Implantation - the Nordic Aortic Valve Intervention-3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rikshospitalet University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of routine FFR-guided complete
      revascularization with PCI compared to conservative management in patients with concomitant
      coronary artery disease who are undergoing TAVI.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality, myocardial infarction, or urgent PCI</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients experiencing all-cause mortality, myocardial infarction, or urgent PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients experiencing all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients experiencing myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent PCI</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients experiencing urgent PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality or myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality, myocardial infarction, or urgent PCI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality or myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission for new onset of heart failure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural (PCI) myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural (TAVI) myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality, myocardial infarction, or urgent PCI</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke or transient ischemic attack (TIA)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCS and NYHA class</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">452</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>TAVI</condition>
  <condition>PCI</condition>
  <arm_group>
    <arm_group_label>TAVI only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>TAVI is performed according to current guidelines and the choice of valve prosthesis is at the operators' discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVI + FFR-guided complete revascularization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAVI is performed according to current guidelines and the choice of transcatheter heart valve is at the operators' discretion. PCI is performed in any suitable lesion with diameter stenosis &gt; 90% or FFR &lt; 0.80.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <description>FFR guided PCI</description>
    <arm_group_label>TAVI + FFR-guided complete revascularization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Severe aortic valve stenosis* and selected for TAVI by a multi-disciplinary Heart
             Team

          3. Concomitant CAD (at least one stenosis with FFR &lt; 0.80 or diameter stenosis &gt; 90%)

        And one of the following:

          1. Symptomatic (dyspnea corresponding to New York Heart Association (NYHA) class II or
             higher, angina pectoris, or cardiac syncope) or

          2. Asymptomatic but have a decline in left ventricular ejection fraction (LVEF), new
             onset of atrial fibrillation, or LV septal hypertrophy

        Exclusion Criteria:

          1. Life expectancy &lt; 1 year due to other severe non-cardiac disease

          2. Severe renal failure with estimated glomerular filtration rate &lt; 20 ml/min

          3. No PCI-eligible coronary artery stenosis, but rotablation is allowed

          4. Admitted with a new acute coronary syndrome (ST-elevation myocardial infarction
             (STEMI) or non-STEMI) within 14 days

          5. Significant stenosis in left main stenosis, left main equivalent (proximal left
             anterior descending artery (LAD) + proximal left circumflex artery (LCx)) or proximal
             LAD + proximal right coronary artery (RCA)

          6. Only stenoses with thrombolysis in myocardial infarction grad &lt; 3

          7. Potential pregnancy

          8. Known allergy towards P2Y12 receptor antagonists, heparin or contrast medium

          9. More than one chronic total occlusion (CTO)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Engstrøm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Søndergaard, MD, MDSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob Lønborg, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob Lønborg, MD, PhD</last_name>
    <email>jacob.thomsen.loenborg@regionh.dk</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 21, 2017</lastchanged_date>
  <firstreceived_date>February 11, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Thomas Engstrom</investigator_full_name>
    <investigator_title>Consultant, PhD, DMSci</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
